RxDoctor Payments Data

Brian Kirsh, MD

Gastroenterology · Washington, DCNPI 1871592493

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.

$7,755in general payments, 2019–2025

Across 319 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bristol Myers Squibb$790
  • Sanofi$643
  • Johnson & Johnson$630
  • Pfizer$556
  • Takeda Pharmaceuticals U.S.A., Inc.$477
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$7,731100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,755 in reported general payments places this provider in the 75th percentile of 77 gastroenterology providers in District of Columbia.

See all gastroenterology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$276,558
Medicare patients
376
Services billed
9,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates105$6,188
Mesalamine20$4,088
Pantoprazole Sodium54$1,063
Omeprazole47$695
Famotidine19$347
Dicyclomine Hcl13$187
Ondansetron OdtOndansetron12$169

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →